New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 100mg - tablet - 100 mg - active: sodium valproate 100mg excipient: hydrated silica light kaolin magnesium stearate maize starch purified water - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 200mg; sodium valproate 200mg; sodium valproate 200mg - modified release tablet - 200 mg - active: sodium valproate 200mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray violet k-1-4613 polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 200mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 200mg excipient: calcium silicate magnesium stearate povidone purified talc violet enteric coat excipient blend violet sub-coat excipient blend - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 500mg; sodium valproate 500mg; sodium valproate 500mg - modified release tablet - 500 mg - active: sodium valproate 500mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 500mg excipient: calcium silicate citric acid diethyl phthalate hypromellose macrogol 6000 magnesium stearate opaspray polyvinylacetate phthalate povidone purified talc stearic acid active: sodium valproate 500mg excipient: calcium silicate magnesium stearate povidone purified talc violet enteric coat excipient blend violet sub-coat excipient blend - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 40 mg/ml;   - oral solution - 200 mg/5ml - active: sodium valproate 40 mg/ml   excipient: cherry flavour 17.40.0740 citric acid hyetellose ponceau 4r purified water saccharin sodium sodium methyl hydroxybenzoate sodium propyl hydroxybenzoate sorbitol - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - insulin glargine 100 iu/ml equivalent to 3.6378 mg/ml - solution for injection - 100 iu/ml - active: insulin glargine 100 iu/ml equivalent to 3.6378 mg/ml excipient: glycerol hydrochloric acid metacresol polysorbate 20 sodium hydroxide water for injection zinc chloride - lantus is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 or type 2 diabetes mellitus patients who require insulin for the control of hyperglycaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - insulin glargine 3.6378 mg/ml (100 iu/ml) - solution for injection - 100 iu/ml - active: insulin glargine 3.6378 mg/ml (100 iu/ml) excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc chloride - lantus is an insulin analogue indicated for once-daily subcutaneous administration in the treatment of type 1 or type 2 diabetes mellitus patients who require insulin for the control of hyperglycaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total));  ;   - film coated tablet - 240 mg - active: vemurafenib 240mg (as a co-precipitate with hypromellose acetate succinate (800 mg total))     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose iron oxide red macrogol 3350 magnesium stearate polyvinyl alcohol purified talc titanium dioxide - indicated for the treatment of unresectable stage iiic or stage iv metastatic melanoma positive for the braf v600 mutation.

Ireland - English - HPRA (Health Products Regulatory Authority)

orion corporation - estradiol - gel - 0.1% w/w 1 milligram(s)/dose - natural and semisynthetic estrogens, plain; estradiol

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - 33664 - cruciate-retaining total knee prosthesis - the universal patella is used to resurface the patella in either primary or revision total knee arthroplasty and is compatible with the implant systems vega, e.motion, columbus and enduro. the rear of the patella implant has 3 pegs for fixation in the bone. cement pockets on the under surface of the patella guarantee the minimum thickness of the cement mantle. the patella implants are made out of uhmwpe and include x-ray markers made out of stainless steel. the implant is used as a component part of a human knee endoprosthesis in combination with aesculap knee endoprosthetic components. indicated for use in severe knee joint conditions that cannot be treated through other therapies: ? degenerative osteoarthritis ? rheumatoid arthritis ? posttraumatic arthritis ? symptomatic knee instability ? knee stiffness ? deformation of the knee joint the surgeon can select the optimum solution for the patient from the various implant types of the knee systems, according to the severity of the condition. the surgeon is responsible for correctly establishing the indication.

Australia - English - Department of Health (Therapeutic Goods Administration)

life healthcare pty ltd - 33692 - rotating hinged total knee prosthesis - composed of tial6v4 with silver anti-infective coating. to be combined with the mutars modular proximal tibia to bridges bone defects in the area of the proximal tibia. design has a retention ring for securing a pet mesh soft tissue attachment tube. the connecting part is attached to the modular proximal tibia component by the means of two screws. the distal end of the connecting part provides a cylindrical fit connection for connecting with a tibial stem and/or extension piece(s). a component of the mutars system intended to be used as a component of a replacement for the proximal section of the tibia as part of a total knee replacement or revision. primary indication for the use of the mutars systems is after bone resection because of a tumour. further indications for the use of the mutars systems are massive bone loss such as in morbus gorham or for the revision arthroplasty and for the prosthetic treatment in case of fractures, pseudarthrosis and arthrosis. the silver coated surface builds a long term prophylaxis against the colonisation of human pathogenic bacteria such as staphylococcus aureus and epidermis, exclusive enterobacteriae and should not be considered as acute treatment.